MedPath
Found 1 clinical trials|View Analysis
Sort by:

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Phase 2
Terminated
Conditions
Leukemia, Myelogenous, Acute
Interventions
Biological: Natural Killer Cells
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Denileukin diftitox
Procedure: Donor lymphapheresis
Drug: IL-2
First Posted Date
2010-04-20
Last Posted Date
2017-12-28
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
15
Registration Number
NCT01106950
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath